Agenus completes enrollment in randomized phase 2 clinical trial of botensilimab/balstilimab in advanced colorectal cancer

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in activate-colorectal, a randomized phase 2 trial in advanced colorectal cancer (crc) evaluating the efficacy and safety of botensilimab (bot) as monotherapy and in combination with balstilimab (bal) or standard of care in patients with metastatic heavily pre-treated colorectal cancer. the phase 2.
AGEN Ratings Summary
AGEN Quant Ranking